
Cellbyte raises $2.75m to fund pharma drug launch platform
Esme Needham | November 27, 2025 | News story | Product launch | AI, Cellbyte, biotech
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of pharmaceutical drug launches.
The complexity of steps such as pricing and reimbursement strategies, regulatory approval and data collection means that novel, life-saving drugs can take over a year to reach the patients who need them. Pharmaceutical companies often spend hundreds of thousands of dollars to access and complete market data in advance of a drug launch. Cellbyte’s AI-native platform, however, is designed to allow drug launch teams to rapidly analyse millions of data points. It aims to determine the most effective launch sequences and market strategies, reducing cost, time and labour.
Cellbyte’s goal is to replace outdated legacy databases, reducing data processes that previously took up to a year to a matter of minutes without loss of quality.
“I’ve seen countless innovations transforming clinical development. Yet in pricing and market access, decisions still too often rely on manual work and anecdotal evidence even though information is so abundant. Now, generative AI is changing that,” said Daniel Moreira, co-CEO and co-founder at Cellbyte.
Felix Steinbrenner, co-CEO and co-founder at Cellbyte, said: “The industry is ready to rethink drug launch workflows and adopt faster, higher quality and cost-effective processes.”
Related Content

Sofinnova and AWS collaborate on AI tools for life sciences
Sofinnova Partners has announced a collaboration with Amazon Web Services (AWS) aimed at expanding the …

Practical AI toolkit launched to help manufacturers cut through complexity
A new guide from Made Smarter is helping manufacturers cut through the noise around AI …

Bramacare launches new AI platform to improve eating disorder care
Bramacare has launched an AI-enabled platform designed to aid eating disorder and rehabilitation services, the …






